Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 112Breast Neoplasms 79Neoplasms 74Neoplasm Metastasis 63Colorectal Neoplasms 62Prostatic Neoplasms 57Recurrence 56Pancreatic Neoplasms 54Leukemia, Myeloid, Acute 54Ovarian Neoplasms 53Multiple Myeloma 50Melanoma 39Glioblastoma 38Squamous Cell Carcinoma of Head and Neck 33Lung Neoplasms 33Triple Negative Breast Neoplasms 31Lymphoma, Non-Hodgkin 30Endometrial Neoplasms 30Precursor Cell Lymphoblastic Leukemia-Lymphoma 29Lymphoma 27Carcinoma, Renal Cell 27Lymphoma, Large B-Cell, Diffuse 26Stomach Neoplasms 25Lymphoma, B-Cell 25Carcinoma, Hepatocellular 24Advanced Solid Tumor 24Small Cell Lung Carcinoma 23Leukemia, Lymphocytic, Chronic, B-Cell 23Burkitt Lymphoma 23Brain Neoplasms 23

Interventions

toripalimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Pancreatic Cancer Metastatic × 90 days × Clear all
NCT07040228 2026-05-18

A Phase Ib/II Clinical Study of Regorafenib Combined With Toripalimab and Albumin-bound Paclitaxel for the Third-line Treatment of Advanced Pancreatic Cancer

Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center

Phase 1/2 Recruiting
23 enrolled
Gastrointestinal

Pancreatic Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡